AR004698A1 - Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados - Google Patents

Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados

Info

Publication number
AR004698A1
AR004698A1 ARP960104941A ARP960104941A AR004698A1 AR 004698 A1 AR004698 A1 AR 004698A1 AR P960104941 A ARP960104941 A AR P960104941A AR P960104941 A ARP960104941 A AR P960104941A AR 004698 A1 AR004698 A1 AR 004698A1
Authority
AR
Argentina
Prior art keywords
alkyl
6alkyl
substituted
formula
ar3c1
Prior art date
Application number
ARP960104941A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR004698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR004698A1 publication Critical patent/AR004698A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Derivados de piperazina 1-(piperidinil-1, 2-disustituido)-4-sustituidas de la fórmula (I), una forma de N-óxido, una sal de adición farmacéuticamenteaceptable o una forma estereoquímicamente isomérica del mismo, en el cual n es 0, 1 ó 2; m es 1 ó2 , siempre que si m es 2, luego n sea 1; p es 1 ó 2;=Q es =Oó =NR3; X es un enlace covalente o un radical bivalente de la fórmula -O-, -S-, -NR3-, R1 es Ar1, Ar1C1-6alquilo o di(Ar1)C1-6alquilo, donde cada grupo alquiloC1-6 es optativamentesustituido con hidroxi, alquiloxi C1-4, oxo o un sustituyente oxo cetalizado de la fórmula -O-CH2-CH2-O- ó -O-CH2-CH2-CH2-O-;R2 es Ar2, Ar2C1-6alquilo, Het1 ó Het1C1-6alquilo; R3 es H ó alquilo C1-6; L es H; Ar3, alquilo C1-6; alquilo C1-6 sustitui do con 1 ó 2 sustitutyentesseleccionados entre hidroxi, alquiloxi C1-6; Ar3, Ar3C1-6alquiloxi y Het2, alquenilo C3-6; Ar3, Ar3C1-6alquenilo; di(Ar3)C3-6alquenilo o un radical de lafórmula (a1-), (a-2), (a-3), (a4) ó (a-5), donde cadaq,independi entemente, es 2, 3 ó 4; cada r es 0,1, 2, 3 ó 4; cada Y1 es independientemente un enlacecovalente, -O- ó NR3; Y2 es un enlace covalente, alcanodiilo C1-4 ó C1-4alquil NR3-; cada -A=B independientemente, es un radical bivalente de lafórmula -CH=CH- ,-N=CH- ó -CH=N-; cada R4 independientemente, es H, alquilo C1-6; Ar2, Ar2 C1-6alquilo; R5 es H, alquilo C1-6; ó Ar3; R6 es alquilo C1-6; Ar3, ArC1-6alquilo; di(Ar3)C1-6alquilo, Ar3C3-7cicloalquilo, ó indolilo; R7 es Ar3 Ar3C1-6alquilo; di (Ar3)C1 -6alquilo; alquilo C1-6; cicloalquiloC3-7, cicloalquilo C3-7sustituido con Ar3, oxazolilo;oxazolilo sustituido con halo o alquilo C1-6; tiazolilo; tiazolilo sustituido con halo o alquilo C1-6; imidazolilo,imidazolilosustituído con Ar3, alquilo C 1-6, Ar3C1-6 alquilo, o halo; indolinilo, indolinilo sustituído con alquilo C1-4
ARP960104941A 1995-10-30 1996-10-28 Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados AR004698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202929 1995-10-30

Publications (1)

Publication Number Publication Date
AR004698A1 true AR004698A1 (es) 1999-03-10

Family

ID=8220780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104941A AR004698A1 (es) 1995-10-30 1996-10-28 Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados

Country Status (31)

Country Link
US (3) US6197772B1 (es)
EP (1) EP0862566B1 (es)
JP (1) JP3073238B2 (es)
KR (1) KR100407067B1 (es)
CN (2) CN100415716C (es)
AR (1) AR004698A1 (es)
AT (1) ATE188691T1 (es)
AU (1) AU704155B2 (es)
BR (1) BR9611184B8 (es)
CA (1) CA2234096C (es)
CY (1) CY2177B1 (es)
CZ (1) CZ291794B6 (es)
DE (1) DE69606196T2 (es)
DK (1) DK0862566T3 (es)
EA (1) EA000909B1 (es)
ES (1) ES2143238T3 (es)
GR (1) GR3033154T3 (es)
HR (1) HRP960507B1 (es)
HU (1) HU227341B1 (es)
IL (1) IL123962A (es)
MX (1) MX9803407A (es)
MY (1) MY116575A (es)
NO (1) NO310232B1 (es)
NZ (1) NZ321575A (es)
PL (1) PL185029B1 (es)
PT (1) PT862566E (es)
SI (1) SI0862566T1 (es)
TR (1) TR199800756T2 (es)
TW (1) TW460473B (es)
WO (1) WO1997016440A1 (es)
ZA (1) ZA969090B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
WO1999032486A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
SI1373256T1 (sl) 2001-03-29 2005-12-31 Schering Corp Antagonisti CCR5, uporabni pri zdravljenju AIDS-a
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
DE60327765D1 (de) 2002-06-24 2009-07-09 Janssen Pharmaceutica Nv Verfahren zur herstellung von n-(2,6-dimethylphenyl)-2-piperazin-1-ylacetamid
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
PL377215A1 (pl) * 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
AU2002368487A1 (en) * 2002-12-23 2004-07-14 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
AU2003298369B2 (en) * 2002-12-23 2009-08-27 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
DE602004013772D1 (de) * 2003-06-10 2008-06-26 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen
JP2006527236A (ja) * 2003-06-10 2006-11-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ オピオイド鎮痛薬と組合せた置換１，４−ジ−ピペリジン−４−イル−ピペラジン誘導体ならびに疼痛およびオピオイドに基づく処置に伴う副作用の処置のためのそれらの使用
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
EP1734966B1 (en) 2004-04-13 2013-07-31 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005123081A2 (en) * 2004-06-22 2005-12-29 Janssen Pharmaceutica N.V. (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
US20060024481A1 (en) * 2004-07-29 2006-02-02 Eastman Kodak Company Jet printing of patterned metal
AU2005277578B2 (en) 2004-08-19 2010-03-18 Monsanto Technology Llc Glyphosate salt herbicidal composition
US7635698B2 (en) * 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8604200B2 (en) 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101913076B (zh) * 2010-06-23 2012-09-05 中国科学院自动化研究所 基于工业机器人的活塞、活塞销和连杆装配方法及装置
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
PT3732994T (pt) 2013-02-08 2022-12-02 Gen Mills Inc Produtos alimentares com reduzido teor de sódio
MX2016008131A (es) 2013-12-20 2016-09-16 Astex Therapeutics Ltd Compuestos heterociclos biciclicos y sus usos en terapia.
PL3377064T3 (pl) * 2016-01-08 2020-02-28 Nerre Therapeutics Limited Orwepitant do leczenia przewlekłego kaszlu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CN1042335C (zh) * 1993-01-03 1999-03-03 诺瓦提斯公司 1－酰基哌啶化合物、其制备方法、药物组合物及用途
EP0625504B1 (de) * 1993-05-12 1997-08-27 HEUMANN PHARMA GmbH Stabile und kristalline Form von Bezafibrat
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
WO1995011895A1 (en) * 1993-10-26 1995-05-04 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
RU2156763C2 (ru) * 1994-07-15 2000-09-27 Мейдзи Сейка Кабусики Кайся Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний
DE69525355T2 (de) * 1994-09-30 2002-09-19 Novartis Ag 1-acyl-4-aliphatische aminopiperidin verbindungen
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
TW460473B (en) 2001-10-21
CY2177B1 (en) 2002-08-23
HRP960507B1 (en) 2001-08-31
TR199800756T2 (xx) 1998-07-21
JP3073238B2 (ja) 2000-08-07
ZA969090B (en) 1998-04-29
HU227341B1 (en) 2011-04-28
PT862566E (pt) 2000-06-30
BR9611184B8 (pt) 2015-02-18
MY116575A (en) 2004-02-28
CN100415716C (zh) 2008-09-03
NO310232B1 (no) 2001-06-11
ES2143238T3 (es) 2000-05-01
SI0862566T1 (en) 2000-04-30
GR3033154T3 (en) 2000-08-31
DE69606196T2 (de) 2000-09-21
US6521621B1 (en) 2003-02-18
CN1117744C (zh) 2003-08-13
EP0862566B1 (en) 2000-01-12
MX9803407A (es) 1998-09-30
USRE37886E1 (en) 2002-10-15
HRP960507A2 (en) 1998-02-28
HUP9802985A3 (en) 2002-10-28
CZ132298A3 (cs) 1998-09-16
US6197772B1 (en) 2001-03-06
DK0862566T3 (da) 2000-06-13
NO981534D0 (no) 1998-04-03
BR9611184A (pt) 1999-03-30
CZ291794B6 (cs) 2003-05-14
PL327406A1 (en) 1998-12-07
KR19990064178A (ko) 1999-07-26
NZ321575A (en) 1999-05-28
AU7493296A (en) 1997-05-22
DE69606196D1 (de) 2000-02-17
JPH11514634A (ja) 1999-12-14
CA2234096C (en) 2005-06-14
IL123962A (en) 2001-01-11
WO1997016440A1 (en) 1997-05-09
CN1438220A (zh) 2003-08-27
ATE188691T1 (de) 2000-01-15
AU704155B2 (en) 1999-04-15
PL185029B1 (pl) 2003-02-28
NO981534L (no) 1998-06-24
EP0862566A1 (en) 1998-09-09
CA2234096A1 (en) 1997-05-09
EA000909B1 (ru) 2000-06-26
CN1205699A (zh) 1999-01-20
EA199800404A1 (ru) 1998-10-29
KR100407067B1 (ko) 2004-06-04
HUP9802985A2 (hu) 1999-10-28

Similar Documents

Publication Publication Date Title
AR004698A1 (es) Derivados de piperazina 1-(piperidinil -1,2- disustituido) -4- sustituida, composicion que los contiene, proceso para preparar dicha composicion y proceso para preparar dichos derivados
MY117557A (en) 1-(1,2-disubstituted piperidinyl)-4- substituted piperidine derivatives
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
MY115864A (en) 1,3-dihydro-indol-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them
AR002241A1 (es) Derivado de 2,4-oxazolidinadiona, composicion farmaceutica que lo comprende y metodo de preparacion del mismo.
ES438081A1 (es) Procedimiento para la obtencion de derivados 1, 2, 4-tria- zol.
AR030553A1 (es) Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados
AR005278A1 (es) Derivados de 1- (piperidinil 1,2 - disustituido) -4- (imidazol fusionado) -piperidina, proceso para la preparación de los mismos, composición farmacéutica que los contiene y proceso para la preparación de dicha composición.
SE7714660L (sv) Aminosockerderivat, sett for framstellning derav samt anvendning derav som lekemedel
AR021888A1 (es) Derivados de espiro-benzazepina-piperidina, composiciones farmaceuticas que los comprenden, proceso para preparar dichas composiciones, intermediario util en la preparacion de dichos derivados, procesos para preparar dichos derivados y procesos para preparar dicho intermediario
TR199801218T2 (xx) Takikinin antagonistleri olarak N-asil-2-ikameli-4-(Benzimidazolil-ya da imidazopiridinil-ikameli art�klar)-piperidinler.
YU48089B (sh) Novi derivati tetrazola i postupak za njihovo pripremanje
DE69301357D1 (de) Indol derivate als "5-ht1-like" agonisten
CO5640109A2 (es) Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen
ES346521A1 (es) Un procedimiento para la preparacion de derivados de sulfo-nilurea.
AR047274A1 (es) Derivados de oxazoltetraciclinas como antibioticos. metodos de obtencion y composiciones farmaceuticas.
AR008168A1 (es) Compuestos etilamino arilamida aril substituidos de pirrolidinilo y pirrolinilo, composicion farmaceutica que lo contiene, compuesto util para susintesis, procedimiento para su preparacion
AR026225A1 (es) Compuestos relacionados con el sistema del periodo circadiano
ES2069768T3 (es) Hidrazonas.
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
ES2038654T3 (es) Un procedimiento para preparar derivados de tianafteno.
KR860003242A (ko) 5-플루오로우라실 유도체의 제조방법
DK299584A (da) Hidtil ukendte prostacyklinderivater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
CO5180536A1 (es) Inhibidores de proteasas catepsina
CO4750648A1 (es) 5-naftalen-1-il-1,3 dioxanos, su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration